A Swiss government agency that last month opened an antitrust investigation into several drug makers and distributors has now disclosed the names of nearly a dozen companies that may have fixed the market for an ingredient used to make a treatment for stomach pain.
In a notice published on Tuesday, the Swiss Competition Commission identified Boehringer Ingelheim and 10 other companies or related subsidiaries that are believed to have established minimum pricing for scopolamine butylbromide, and then divided the market by regions. The treatment is marketed as Buscopan as well as other names and is also used to treat renal colic and bladder spasms.
About the Author Reprints
